| Species |
Human |
| Protein Construction |
FGF-21 (His29-Ser209)
Accession # Q9NSA1 |
Poly-His |
| N-term |
C-term |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 0.3 μg/ml, measured in a bioassay using NIH-3T3 cells. |
| Expression System |
CHO |
| Apparent Molecular Weight |
23~25 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
FGF-21, also known as fibroblast growth factor-21 and FGFL, is a secreted growth factor belonging to theheparin-binding growth factor family. It is produced by hepatocytes in response to fatty acid stimulation. FGF-21 couples with its co-factor beta-Klotho to signal through FGFR1c and FGFR4. Signal transduction results in insulin-independent uptake of glucose by adipocytes. Clinical administration of FGF-21 induces energy expenditure, fat utilization and lipid excretion. |
| Synonyms |
FGF21; fibroblast growth factor-21; FGFL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
